Bruno Coudert
机构: Centre Georges Francois Leclerc Dijon France
每年引用次数
引用次数
引用: 17,349
H-指数: 60
I10-指数 : 124
出版物: 426
Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small-cell lung cancer (NSCLC)
F Cappuzzo , B Coudert , R Wierzbicki , K Park
EJC SUPPLEMENTS 7 ( 3) 13 -13
17
2009
Survival benefit with erlotinib maintenance therapy relative to prior chemotherapeutic response: A subanalysis of the phase III SATURN study in NSCLC
B Coudert , T Ciuleanu , K Park , Y Wu
JOURNAL OF THORACIC ONCOLOGY 5 ( 5) S80 -S80
5
2010
IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
O Molinier , B Besse , F Barlesi , C Audigier-Valette
ESMO open 7 ( 1) 100353 -100353
14
2022
EGFR, ALK, KRAS prognostic value in a large French prospective cohort of non-previously treated advanced NSCLC. Preliminary report of the IFCT-PREDICT. amm cohort
J Cadranel , E Quoix , M Duruisseaux , S Friard
European Journal of Cancer 51 S646 -S646
1
2015
Données d’efficacité et de tolérance d’un essai de phase 2 international, en ouvert, à un bras d’alectinib (NP28673), chez des patients atteints d’un cancer bronchique non à petites cellules (CBNPC) ALK+ en échec au crizotinib
H Lena , P Do , E Dansin , G Robinet
Revue des Maladies Respiratoires 33 A48 -A48
2016
Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases
Everett E Vokes , N Ready , E Felip , L Horn
Annals of Oncology 29 ( 4) 959 -965
204
2018
Population pharmacokinetics and exposure–response relationship of trastuzumab and bevacizumab in early-stage breast cancer
A Petitcollin , N Azzopardi , JY Pierga , D Ternant
European Journal of Clinical Pharmacology 77 1861 -1873
2
2021
Neoadjuvant chemotherapy for breast cancer is not effective on overall survival nor mastectomy rate in a population-based study with 11-years median follow-up
I Ferrieres , Le Ray , S Dabakuyo , P Maingon
FUNDAMENTAL & CLINICAL PHARMACOLOGY 25 85 -85
2011
Cancer du sein avec atteinte ganglionnaire: suivi à long terme de l'étude PACS 01 (FNCLCC)
B Coudert , M Campone , G PIOT , T PETIT
La Lettre du sénologue ( 48)
2010
Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (ADD)/mixed aligoastrocytoma (MOA) and anaplastic astracytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDOG) and Brain Tumor Group
M van den Bent , A Brandes , M Frenay , P Fumoleau
Journal Of Clinical Oncology 23 ( 16) 118S -118S
7
2005
European Organisation for Research and Treatment of Cancer Chronotherapy Group. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group
S Giacchetti , G Bjarnason , C Garufi , D Genet
J Clin Oncol 24 ( 22) 3562 -3569
33
2006
Evaluation of tumour blood flow with dynamic 18F-fluorodeoxyglucose positron emission tomography: correlation with microvessel density.
A Cochet , B Khoury , S Pigeonnat , A Berriolo-Riedinger
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 38 S141 -S141
1
2011
Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy in luminal breast cancer, using 18F-FDG PET
O Humbert , A Berriolo-Riedinger , A Cochet , M Gauthier
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 39 S283 -S284
2012
FDG PET/CT provides powerful prognostic stratification in the primary staging of breast cancer
A Cochet , I Dygai-Cochet , J Riedinger , O Humbert
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 39 S284 -S284
2012
18F-FDG PET baseline tumoral uptake and early response to neoadjuvant chemotherapy: relevance of breast cancer subtype
A Berriolo-Riedinger , O Humbert , J Riedinger , B Coudert
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 38 S217 -S217
2011
Prognostic value at 4 year, of the decrease of tumoral glucidic metabolism, evaluated with 18F-FDG PET, after the first course of neoadjuvant chemotherapy in operable breast cancer
O Humbert , A Berriolo-Riedinger , J Riedinger , B Coudert
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 38 S217 -S217
2011
18 [F]-FDG Tumoral Uptake and Metabolic Response after 1 Cycle of Primary Chemotherapy According to Tumoral Phenotype of Breast Cancer
A Berriolo-Riedinger , O Humbert , JM Riedinger , L Arnoud
CANCER RESEARCH 70
2010
Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy
B Coudert , T Ciuleanu , K Park , Y-L Wu
Annals of Oncology 23 ( 2) 388 -394
136
2012
Metastatic inflammatory breast cancer: Clinical features and outcomes in the national, multicentric, real-life ESME cohort
A Monneur , F Bertucci , A Lardy-Cleaud , P Augereau
CANCER RESEARCH 79 ( 4)
2019
European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a european organisation for research and treatment of cancer brain tumor group study
E Raymond , AA Brandes , C Dittrich , P Fumoleau
J Clin Oncol 26 ( 28) 4659 -65
25
2008